Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-25T14:49:04.429Z Has data issue: false hasContentIssue false
  • English
  • Français

Two years of maintenance treatment with venlafaxine xr 75-225 mg/d: Efficacy in patients with recurrent unipolar major depression

Published online by Cambridge University Press:  16 April 2020

J.H. Kocsis ,
S.G. Kornstein ,
S. Ahmed ,
T. Ferdousi ,
J. Musgnung ,
M. Thase ,
E. Friedman ,
B.W. Dunlop ,
B. Yan  and
R. Pedersen
...Show all authors
J.H. Kocsis
Affiliation:
Department of Psychiatry, Weill Cornell Medical College, New York, NY, USA
S.G. Kornstein
Affiliation:
Mood Disorders Institute, Virginia Commonwealth University, Richmond, VA, USA
S. Ahmed
Affiliation:
Wyeth Pharmaceuticals, Collegeville, PA, USA
T. Ferdousi
Affiliation:
Wyeth Pharmaceuticals, Collegeville, PA, USA
J. Musgnung
Affiliation:
Wyeth Pharmaceuticals, Collegeville, PA, USA
M. Thase
Affiliation:
Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
E. Friedman
Affiliation:
Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
B.W. Dunlop
Affiliation:
Department of Psychiatry, Emory University School of Medicine, Atlanta, GA, USA
B. Yan
Affiliation:
Wyeth Pharmaceuticals, Collegeville, PA, USA
R. Pedersen
Affiliation:
Wyeth Pharmaceuticals, Collegeville, PA, USA
P.T. Ninan
Affiliation:
Wyeth Pharmaceuticals, Collegeville, PA, USA

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

The efficacy of venlafaxine extended-release (XR) at doses between 75 mg/d and 300 mg/d has been demonstrated in patients with recurrent major depressive disorder (MDD) over 2.5 years. This analysis evaluated the long-term efficacy of venlafaxine XR ≤225 mg/d, the approved dosage in many countries.

Methods:

In the primary multicenter, double-blind trial, outpatients with recurrent MDD (N=1096) were randomized to receive 10-week acute-phase treatment with venlafaxine XR (75 mg/d to 300 mg/d) or fluoxetine (20 mg/d to 60 mg/d), followed by a 6-month continuation phase. Subsequently, at the start of 2 consecutive, double-blind, 12-month maintenance phases, venlafaxine XR responders were randomized to receive venlafaxine XR or placebo. Data from the 24 months of maintenance treatment were analyzed for the combined end point of maintenance of response (ie, no recurrence of depression and no dose increase above 225 mg/d), and each component individually. Time to each outcome was evaluated with Kaplan-Meier methods using log-rank tests for venlafaxine XR-placebo comparisons.

Results:

The analysis population included 114 patients who had received venlafaxine XR doses less than or equal to 225 mg/d prior to maintenance phase baseline (venlafaxine XR: n=55; placebo: n=59). Probability estimates for maintaining response were 70% for venlafaxine XR and 38% for placebo (P=0.007), for no dose increase were 76% and 58%, respectively (P=0.019), and for no recurrence were 87% vs 65%, respectively (P=.099).

Conclusions:

These data confirm venlafaxine XR is effective maintaining response at doses ≤225 mg/d for up to 2.5 years in patients with MDD.

Type
Poster Session 2: Depressive Disorders
Information
European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S239 - S240
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.